Skip to content
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
Home/Events/2026 Global XDC Innovation Conference
2026 Global XDC Innovation Conference
EventsConferences

2026 Global XDC Innovation Conference

By Chris Chen
August 31, 2026 1 Min Read
0

Explore the new frontiers of XDC fusion and breakthrough innovation – under the theme: Convergence & Innovation: The New Frontiers of Bioconjugation.

Highlights Sneak Peek
🔹 Focused Innovation Agenda – Key XDC technologies and emerging modalities, from discovery to commercial application.
🔹 BioPartnering Session – Connecting asset originators with pharma, investors, and licensing partners through focused talks and 1:1 meetings.
🔹 Global Networking & Impact – Cross-border dialogue with industry leaders to advance XDC together.

Don’t miss the chance to connect, collaborate, and co-create the future of XDC. See you in Wuxi this September!

Dates: Sept 17-19, 2026

Location: Intercontinental Wuxi, Wuxi, China (No.6 Yong He Road, Liangxi District, Wuxi, Jiangsu Province, China)

REGISTER

Tags:

ADCBioconjugationBioPartneringDrugDiscoveryXDC
Other Articles
Scientific illustration of Ascletis’ ASC30 once-daily oral small-molecule GLP-1 receptor agonist, showing GLP-1 receptor binding, appetite and gastrointestinal effects, weight reduction and global Phase III clinical development.
Previous

Ascletis Doses First Participant in Global Phase III Program of Oral GLP-1 Drug ASC30

Illustration of Simnova’s next-generation cell therapy platforms, including off-the-shelf CAR-NK, in vivo CAR-T, engineered immune cells, and cell therapy manufacturing.
Next

Simnova Raises Nearly RMB 400 Million in Series B Financing to Advance CAR-NK and In Vivo CAR-T Platforms

No Comment! Be the first one.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

2026 H2 AbbVie China Partnering Day
2026 Global XDC Innovation Conference

Welcome to BioPharmChina, a dedicated news and information portal covering the rapidly evolving biotechnology and biopharmaceutical industry in China.

Get the latest news in China's BioPharma industry delivered straight to your inbox.

Latest Articles

  • Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
  • Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
  • 1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
  • Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
  • Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3

Info

    About

    Privacy Policy

    Terms of Use

    Newsletter

    Contact

    Contact

    Email
    contact@biopharmchina.com

    Location
    San Francisco, CA, USA

    • X
    • Facebook
    Copyright 2026 — BioPharmChina. All rights reserved.